Oncobiologics Current Ratio 2015-2021 | OTLK

Oncobiologics current ratio from 2015 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Oncobiologics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.03B $0.02B 1.62
2021-03-31 $0.04B $0.02B 1.83
2020-12-31 $0.01B $0.01B 0.91
2020-09-30 $0.02B $0.02B 1.13
2020-06-30 $0.03B $0.02B 1.53
2020-03-31 $0.01B $0.02B 0.40
2019-12-31 $0.01B $0.02B 0.33
2019-09-30 $0.01B $0.02B 0.67
2019-06-30 $0.02B $0.02B 0.81
2019-03-31 $0.00B $0.03B 0.08
2018-12-31 $0.00B $0.03B 0.08
2018-09-30 $0.00B $0.03B 0.10
2018-06-30 $0.01B $0.03B 0.41
2018-03-31 $0.01B $0.03B 0.22
2017-12-31 $0.02B $0.03B 0.49
2017-09-30 $0.00B $0.03B 0.14
2017-06-30 $0.00B $0.04B 0.03
2017-03-31 $0.00B $0.04B 0.03
2016-12-31 $0.00B $0.03B 0.10
2016-09-30 $0.01B $0.02B 0.28
2016-06-30 $0.02B $0.02B 0.65
2016-03-31 $0.00B $0.04B 0.11
2015-12-31 $0.01B $0.04B 0.30
2015-09-30 $0.02B $0.04B 0.41
2015-06-30 $0.00B 0.00
2015-03-31 $0.00B 0.00
2014-12-31 $0.00B 0.00
2014-09-30 $0.00B $0.02B 0.16
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.372B $0.008B
Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing ONS-5010 which is a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration which is in clinical stage. Outlook Therapeutics Inc., formerly known as Oncobiologics Inc., is based in Cranbury, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76